Galapagos NV, of Mechelen, Belgium, said it expects to file plans for an exploratory phase II study of its autotaxin inhibitor, GLPG-1690, in idiopathic pulmonary fibrosis before year-end after finding encouragement in preclinical and phase I results that the company is presenting at the European Respiratory Society Annual Meeting in Amsterdam, the Netherlands.